The latest market report published by Credence Research, Inc. the market for pulmonary arterial hypertension treatment was estimated at US$ 7,802.9 million in 2017 and is projected to reach US$ 14,642.1 million by 2026 for CAGR of 7.6 per cent over the 2018-2026 forecast period.
Market Insights
The market for pulmonary arterial hypertension (PAH) treatment is expected to exhibit a remarkable CAGR during the 2018-2026 forecast period. PAH is a rare, progressive disorder characterized by high blood pressure in the arteries that move from the heart to the lungs. Drivers accountable for market growth are globally growing older population groups, coupled with increasing prevalence of PAH due to causative diseases including lung disease, human immunodeficiency virus (HIV), connective tissue disorders, chronic liver disease, sedentary lifestyle, and other idiopathic conditions.
Browse Full Report Originally Published by Credence Research at https://www.credenceresearch.com/report/pulmonary-arterial-hypertension-pah-treatment-market
In addition, increasing launches of innovative drugs and treatment therapies, favorable initiatives by various governments, and rising expenditure on healthcare are boosting market growth. The European Respiratory Society (ERS) has reported that the global prevalence of PAH ranges from 10 to 52 cases per million and is estimated to be between 100,000 and 200,000 cases per year. Presence of favorable government support in the United States, such as the Orphan Drug Act (ODA) 1983 and the Rare Disease Act (RDA) 2002 to facilitate the development of orphan drugs with benefits, including tax incentives (lower taxes / tax credits equal to half of development costs), clinical research grants, and improved patent protection and marketing rights. In addition, the RDA has been amended to create a centralized structure (statutory authorization) for coordinating research or to recommend national research agendas to better facilitate research and education.
The market dynamics would be varying by the end of 2020 as some of the blockbuster PAH treatment drugs such as Tracleer (bosentan), Adcirca, Letairis, and Tyvaso will go off-patent after 2018 and the entry of generic drugs with reduced prices than patented drugs would get facilitated.
Key Market Movements:
- Globally, the pulmonary arterial hypertension treatment market to exhibit a lucrative growth with a CAGR of 7.6% during the forecast period from 2018 to 2026
- Based on drug class, the vasodilators segment would register the fastest CAGR during the forecast period due to rising number of prescriptions & sale of prostacyclin and prostacyclin analogs such as Flolan (epoprostenol), Remodulin/Orenitram/Tyvaso (treprostinil), Ventavis (iloprost), Uptravi (selexipag), and Veletri (epoprostenol). These vasodilators will surpass the endothelin receptor antagonists (ERAs) in terms of revenue by the end of 2018 due to launch of blockbuster drugs like Uptravi and Ventavis in recent years, and launch of potential pipeline drugs in the near future.
- The presence of key market participants, supportive government initiatives, and sophisticated healthcare infrastructure, and rising prevalence of risk factors for PAH in the U.S. and Canada would facilitate North America's supremacy throughout the forecast period
- Asia Pacific is envisaged to exhibit the fastest market growth over the forecast period and would retain its status quo owing to growing elderly population base coupled with increasing incidence of causative diseases of PAH, and rising spending on healthcare in China, India, Japan, and Australia
- Major players in this vertical are GlaxoSmithKline plc; Pfizer Inc.; Gilead Sciences, Inc.; Novartis International AG; Bayer AG; Merck KGaA; Bristol-Myers Squibb Company; United Therapeutics Corporation; Actelion Pharmaceuticals Ltd; Reata Pharmaceuticals, Inc.; Toray Industries, Inc.; Liquidia Technologies, Inc.; and Nuventra Pharma Sciences
You can get the sample copy of this research by Credence Research here: https://www.credenceresearch.com/sample-request/59330
Table of Content
Chapter 1 Preface
1.1 Report Scope and Description
1.1.1 Study Purpose
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I - Secondary Research
1.3.2 Phase II - Primary Research
1.3.3 Phase III - Expert Panel Review
1.3.4 Approaches Adopted
1.3.4.1 Top-Down Approach
1.3.4.2 Bottom-Up Approach
1.3.5 Assumptions
1.4 Market Segmentation
1.1 Report Scope and Description
1.1.1 Study Purpose
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I - Secondary Research
1.3.2 Phase II - Primary Research
1.3.3 Phase III - Expert Panel Review
1.3.4 Approaches Adopted
1.3.4.1 Top-Down Approach
1.3.4.2 Bottom-Up Approach
1.3.5 Assumptions
1.4 Market Segmentation
Chapter 2 Executive Summary
2.1 Market Snapshot: Global Pulmonary Arterial Hypertension Treatment Market
2.1.1 Global Pulmonary Arterial Hypertension Treatment Market, by Drug Class, 2017 (US$ Mn)
2.1.2 Global Pulmonary Arterial Hypertension Treatment Market, by Geography, 2017 (US$ Mn)
2.1 Market Snapshot: Global Pulmonary Arterial Hypertension Treatment Market
2.1.1 Global Pulmonary Arterial Hypertension Treatment Market, by Drug Class, 2017 (US$ Mn)
2.1.2 Global Pulmonary Arterial Hypertension Treatment Market, by Geography, 2017 (US$ Mn)
Chapter 3 Market Dynamics
3.1 Introduction
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.1.1 Globally Growing Elderly Population Coupled with Rising Prevalence of PAH
3.2.1.2 Driver 2
3.2.2 Challenges
3.2.2.1 Challenge 1
3.2.2.2 Challenge 2
3.2.3 Opportunities
3.2.3.1 Opportunity 1
3.2.3.2 Opportunity 2
3.3 Attractive Investment Proposition, by Geography, 2017
3.4 Market Positioning of Key Players, 2017
3.1 Introduction
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.1.1 Globally Growing Elderly Population Coupled with Rising Prevalence of PAH
3.2.1.2 Driver 2
3.2.2 Challenges
3.2.2.1 Challenge 1
3.2.2.2 Challenge 2
3.2.3 Opportunities
3.2.3.1 Opportunity 1
3.2.3.2 Opportunity 2
3.3 Attractive Investment Proposition, by Geography, 2017
3.4 Market Positioning of Key Players, 2017
Chapter 4 Global Pulmonary Arterial Hypertension Treatment Market, by Drug Class, 2016-2026 (US$ Mn)
4.1 Overview
4.2 Endothelin Receptor Antagonists (ERAs)
4.3 Vasodilators
4.4 Phosphodiesterase-5 (PDE-5) Inhibitors
4.5 Soluble Guanylate Cyclase (sGC) Stimulators
4.6 Calcium Channel Blockers (CCBs)
4.7 Others (anticoagulants, diuretics, and cardiac glycosides)
4.8 Pipeline Analysis
4.8.1 Phase III (Forecast till 2026) (US$ Mn)
4.8.1.1 Beraprost Sodium 314d Modified Release (BPS-314d-MR)
4.8.1.2 LIQ861 Inhaled Treprostinil
4.8.2 Phase II & I (Tabular Format)
4.1 Overview
4.2 Endothelin Receptor Antagonists (ERAs)
4.3 Vasodilators
4.4 Phosphodiesterase-5 (PDE-5) Inhibitors
4.5 Soluble Guanylate Cyclase (sGC) Stimulators
4.6 Calcium Channel Blockers (CCBs)
4.7 Others (anticoagulants, diuretics, and cardiac glycosides)
4.8 Pipeline Analysis
4.8.1 Phase III (Forecast till 2026) (US$ Mn)
4.8.1.1 Beraprost Sodium 314d Modified Release (BPS-314d-MR)
4.8.1.2 LIQ861 Inhaled Treprostinil
4.8.2 Phase II & I (Tabular Format)
Chapter 5 Global Pulmonary Arterial Hypertension Treatment Market, by Geography, 2016-2026 (US$ Mn)
.......................
.......................
You can get the sample copy of this research by Credence Research here: https://www.credenceresearch.com/sample-request/59330
About Credence Research (Original Publisher)
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.
Media Contact
Name: Chris Smith
Address: 105 N 1st ST #429,
SAN JOSE, CA 95103 US
Toll-Free (US/CANADA) Ph.: +1-800-361-8290
E-mail: sales@credenceresearch.com
Website: http://www.credenceresearch.com
No comments:
Post a Comment